Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Assets: 2019-2025

Historic Assets for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to $1.3 billion.

  • Beam Therapeutics' Assets rose 11.93% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 11.93%. This contributed to the annual value of $1.1 billion for FY2024, which is 24.38% down from last year.
  • As of Q3 2025, Beam Therapeutics' Assets stood at $1.3 billion, which was down 5.76% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Assets registered a high of $1.5 billion during Q4 2021, and its lowest value of $693.2 million during Q1 2021.
  • In the last 3 years, Beam Therapeutics' Assets had a median value of $1.3 billion in 2023 and averaged $1.3 billion.
  • As far as peak fluctuations go, Beam Therapeutics' Assets skyrocketed by 315.62% in 2021, and later decreased by 24.38% in 2024.
  • Quarterly analysis of 5 years shows Beam Therapeutics' Assets stood at $1.5 billion in 2021, then decreased by 9.00% to $1.3 billion in 2022, then increased by 8.79% to $1.5 billion in 2023, then declined by 24.38% to $1.1 billion in 2024, then rose by 11.93% to $1.3 billion in 2025.
  • Its Assets stands at $1.3 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.5 billion for Q1 2025.